Slide 1: Second Quarter 2026 Earnings
Second Quarter 2026 Earnings August 4, 2026
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward -looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financia
Slide 3: Key Takeaways
Key Takeaways Innovation Market Performance 2Q financial performance Launch of Signals AI , Signals Continuing improvement above expectations Anthropic connector, and in Pharma/Biotech end Signals for Startups market conditions Strong cash flow . Retired €500m note in July FDA Clearance of Strong Di
Slide 4: 2Q26 Pro Forma Revenue Highlights
2Q26 Pro Forma* Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non -recurring +HSD +LSD +DD $0.7 B -LSD -LSD $0.7 B +LSD $0.7 B +DD *Pro Forma excludes the impact of the China Immunodiagnostics business which the Company has agreed to divest 4
Slide 5: 2Q26 Financial Results
2Q26 Financial Results PRO FORMA REVENUE PRO FORMA ADJ. OP. MARGIN PRO FORMA ADJ. EPS FREE CASH FLOW $711M 29.3% $1.41 $184M +4% y/y +280bps y/y +23% y/y $299M YTD Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI: +3% | M&A: +1% | FX: 0% 62.3% | +200bps y/y 16.0% 108% Adj. Net Interest &
Slide 6: Life Sciences
Life Sciences LIFE SCIENCES SOLUTIONS SOFTWARE PRO FORMA REVENUE ADJUSTED OP. MARGINS -DD -3% Organic Growth 31.1% Total: -2% | M&A: +1% | FX: 0 % -50bps y/y $359 M 2Q26 pro forma • -MSD Pharma/Biotech & -LSD Academic/Gov’t, due to Software revenue declines +LSD • +LSD Life Sciences Solutions, growt
Slide 7: Diagnostics
Diagnostics IMMUNODIAGNOSTICS REPRODUCTIVE PRO FORMA REVENUE ADJUSTED OP. MARGINS HEALTH +11% Organic Growth 30.4% Total: +12% | M&A: 0% | FX: +1% +520 bps y/y +DD $352 M • +HSD ImmunoDx with broad -based strength 2Q26 pro forma +HSD revenue • +DD Reproductive Health with strength in newborn, partne
Slide 8: 2026 Pro Forma Financial Guidance
2026 Pro Forma* Financial Guidance REVENUE $2.83B - $2.86B Total : 5% to 6% Organic: 4% to 5% FX: +0.5%, M&A: +0.75 % ADJUSTED OP. MARGIN 28.7% ADJUSTED EPS $5.30 - $5.40 Adj. net interest expense, other: ~$ 90 M Adj. tax rate: ~18 % Average diluted share count: ~112M *Pro Forma excludes the impact
Slide 9: Revvity.com
Revvity.com